Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $4.72B
• Dividend Yield: N/A
• Average Volume (3M): 689.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.09
• Revenue Growth: -50.05%
• EPS Growth: -54.47%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 71,949,030
• 10 Day Avg. Volume: 738,771
• 30 Day Avg. Volume: 689,442
• PEG Ratio: -0.74
• Price to Book (P/B): 3.61
• Price to Sales (P/S): 64.14
• P/FCF Ratio: -14.56
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 103.34
• Enterprise Value/Gross Profit: -139.30
• Enterprise Value/Ebitda: -15.81
• 1Y Price Target: $73.22
• Price Target Upside: 11.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 20
• EPS Forecast (FY): -3.47
• Revenue Forecast (FY): $58.20M

• Rating: 54 Neutral
• Price Target: $66.00 ▲(0.63% Upside)

Kymera Therapeutics' overall stock score is primarily impacted by its financial challenges, with declining revenues and negative cash flows being significant concerns. The technical analysis provides a positive outlook with bullish momentum, but valuation remains unattractive due to ongoing losses. The earnings call highlights strategic advancements and a strong cash position, but high expenses and trial challenges temper optimism.

Positive Factors

Strategic Partnerships

The partnership with Gilead enhances Kymera's capabilities in oncology, providing access to resources and expertise that can accelerate drug development and expand market reach.

Strong Cash Position

A strong cash position ensures financial stability and supports ongoing R&D activities, allowing Kymera to pursue strategic initiatives without immediate financial constraints.

Pipeline Expansion

Expanding the pipeline with new drug candidates enhances long-term growth prospects by diversifying potential revenue streams and addressing unmet medical needs.

Negative Factors

Declining Revenue

Declining revenue growth indicates challenges in monetizing existing partnerships and products, which could hinder the company's ability to sustain operations and invest in future growth.

High Operational Costs

High operational costs can strain financial resources, reducing the company's ability to invest in new projects and potentially impacting profitability if not managed effectively.

Negative Cash Flow

Negative cash flow poses a risk to financial sustainability, limiting the company's ability to fund operations and invest in growth without external financing.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Kymera Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates. The company may receive upfront payments, research funding, and milestone payments as its products progress through various stages of development. Additionally, Kymera could earn royalties on future sales of any approved therapies stemming from these collaborations. The company's revenue model is heavily reliant on the successful advancement of its therapeutic candidates in clinical trials and the establishment of strategic alliances to enhance its research capabilities and market reach.

Kymera Therapeutics Financial Statement Overview

Summary

Kymera Therapeutics faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. The income statement shows a negative revenue growth rate and net profit margins, while the balance sheet indicates low leverage but poor profitability. The cash flow statement highlights negative operating and free cash flows, posing a risk to financial sustainability.

Income Statement

Kymera Therapeutics shows a declining revenue trend with a negative revenue growth rate of -2.19% in the TTM period. The company has consistently negative net profit margins, with a TTM net profit margin of -6.75%, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Overall, the income statement indicates financial instability and a need for strategic improvements to reverse the negative trends.

Balance Sheet

The balance sheet of Kymera Therapeutics shows a relatively low debt-to-equity ratio of 0.09 in the TTM period, suggesting conservative leverage. However, the return on equity is negative at -33.35%, indicating that the company is not generating profits from its equity base. The equity ratio is not explicitly provided, but the company maintains a solid equity base relative to its assets. While the low leverage is a positive aspect, the negative ROE highlights profitability issues.

Cash Flow

Kymera Therapeutics has negative operating and free cash flows, with a TTM operating cash flow of -$227.93 million and free cash flow of -$230.21 million. The free cash flow growth rate is negative at -8.98%, indicating worsening cash flow conditions. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. The cash flow statement underscores the company's struggle to generate positive cash flows, posing a risk to financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.73M	47.07M	78.59M	46.83M	72.83M	34.03M
Gross Profit	-32.44M	47.07M	78.59M	46.83M	72.83M	34.03M
EBITDA	-285.92M	-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
Net Income	-295.12M	-223.86M	-146.96M	-154.81M	-100.22M	-45.59M
Balance Sheet
Total Assets	1.10B	978.03M	575.76M	603.13M	605.90M	487.18M
Cash, Cash Equivalents and Short-Term Investments	505.68M	488.74M	374.88M	407.17M	442.42M	296.20M
Total Debt	84.00M	87.76M	84.67M	17.34M	17.96M	17.99M
Total Liabilities	155.79M	142.42M	180.79M	112.98M	146.27M	203.29M
Stockholders Equity	946.26M	835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow
Free Cash Flow	-230.21M	-207.34M	-137.31M	-155.92M	-130.54M	79.03M
Operating Cash Flow	-227.93M	-194.50M	-102.83M	-153.09M	-128.95M	88.13M
Investing Cash Flow	-58.09M	-404.08M	139.89M	20.52M	-99.83M	-422.59M
Financing Cash Flow	288.26M	608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.59
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Positive. The current price of 65.59 is above the 20-day moving average (MA) of 62.53, above the 50-day MA of 58.68, and above the 200-day MA of 42.76, indicating a bullish trend. The MACD of 2.09 indicates Negative momentum. The RSI at 63.90 is Neutral, neither overbought nor oversold. The STOCH value of 62.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PTGX	70 Neutral	$5.48B	138.44	7.80%	―	-35.39%	-72.97%
AKRO	60 Neutral	$4.47B	―	-34.53%	―	―	-0.06%
KYMR	54 Neutral	$4.72B	―	-32.09%	―	-50.05%	-54.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APLS	51 Neutral	$2.55B	67.80	14.10%	―	42.11%	―
CRNX	48 Neutral	$4.16B	―	-44.42%	―	―	-21.96%
MLTX	41 Neutral	$938.56M	―	-54.17%	―	―	-157.74%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Reports Q3 2025 Financial Results

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, pioneering the field of targeted protein degradation to address critical health problems.

Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges

Kymera Therapeutics’ recent earnings call painted a picture of a company on the rise, marked by significant advancements in its STAT6 and IRF5 programs and strategic partnerships. The sentiment was largely positive, reflecting a strong financial position and a clear path forward for its pipeline. However, there were notes of caution regarding high expenses and limited data from the Phase Ib trial, along with the challenges posed by placebo effects in trials.

Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis

Kymera Therapeutics, Inc. is conducting a Phase 2b clinical study titled ‘A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis.’ The study aims to assess the effectiveness and safety of KT-621, an oral drug, in reducing the severity of moderate to severe atopic dermatitis, a prevalent form of eczema.

Kymera Therapeutics Announces New Chief Legal Officer

On September 3, 2025, Kymera Therapeutics announced the retirement of Ellen Chiniara as Chief Legal Officer, with Brian R. Adams succeeding her. This leadership change is part of Kymera’s strategic efforts to advance its novel programs in the field of immunology, aiming to redefine treatment possibilities with groundbreaking oral medicines.

The most recent analyst rating on (KYMR) stock is a Hold with a $43.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.